GB0303609D0 - Novel therapeutic method and compositions - Google Patents

Novel therapeutic method and compositions

Info

Publication number
GB0303609D0
GB0303609D0 GBGB0303609.2A GB0303609A GB0303609D0 GB 0303609 D0 GB0303609 D0 GB 0303609D0 GB 0303609 A GB0303609 A GB 0303609A GB 0303609 D0 GB0303609 D0 GB 0303609D0
Authority
GB
United Kingdom
Prior art keywords
compositions
therapeutic method
novel therapeutic
novel
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0303609.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0303609.2A priority Critical patent/GB0303609D0/en
Publication of GB0303609D0 publication Critical patent/GB0303609D0/en
Priority to PCT/US2004/004329 priority patent/WO2004073622A2/en
Priority to US10/545,773 priority patent/US20060159648A1/en
Priority to JP2006503567A priority patent/JP2006517973A/en
Priority to EP04711167A priority patent/EP1594959A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0303609.2A 2003-02-17 2003-02-17 Novel therapeutic method and compositions Ceased GB0303609D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0303609.2A GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions
PCT/US2004/004329 WO2004073622A2 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration
US10/545,773 US20060159648A1 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration
JP2006503567A JP2006517973A (en) 2003-02-17 2004-02-13 Novel therapeutic method and composition for topical administration
EP04711167A EP1594959A4 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303609.2A GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions

Publications (1)

Publication Number Publication Date
GB0303609D0 true GB0303609D0 (en) 2003-03-19

Family

ID=9953158

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0303609.2A Ceased GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions

Country Status (4)

Country Link
EP (1) EP1594959A4 (en)
JP (1) JP2006517973A (en)
GB (1) GB0303609D0 (en)
WO (1) WO2004073622A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050390A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
FR2894477A1 (en) * 2005-12-13 2007-06-15 Galderma Res & Dev USE OF NAVEGLITAZAR FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
PT2396081T (en) 2009-02-16 2017-07-11 Nogra Pharma Ltd Alkylamido compounds and uses thereof
WO2011084824A1 (en) * 2009-12-21 2011-07-14 Sarah Bacus Compositions and methods for increasing cellular fat and bleaching skin
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
BR112014026160A2 (en) 2012-04-18 2017-07-18 Nogra Pharma Ltd Methods To Treat Lactose Intolerance
EP2968298B1 (en) 2013-03-14 2018-01-31 Deuterx, LLC Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
ES2831326T3 (en) 2014-01-15 2021-06-08 Poxel Sa Methods to treat neurological, metabolic, and other disorders using deuterium-enriched enantiopure pioglitazone
EP3500260A1 (en) 2017-02-22 2019-06-26 Sugarman, Jeffrey, L. Glitazones for topical application
EA202192207A1 (en) 2019-02-08 2021-10-27 Ногра Фарма Лимитед METHOD FOR OBTAINING 3- (4'-AMINOPHENYL) -2-METHOXYPROPIONIC ACID AND ITS ANALOGUES AND INTERMEDIATE COMPOUNDS
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
AU2002303156A1 (en) * 2001-03-23 2002-10-08 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands

Also Published As

Publication number Publication date
EP1594959A4 (en) 2006-05-03
JP2006517973A (en) 2006-08-03
WO2004073622A3 (en) 2005-01-20
WO2004073622A2 (en) 2004-09-02
EP1594959A2 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
GB0411940D0 (en) Methods and compositions
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1701725A4 (en) Methods and compositions
EP1603543A4 (en) Therapeutic compositions
GB0222091D0 (en) Dental compositions and methods
AU2003256805A8 (en) Compounds compositions and methods
AU2003287443A8 (en) Compositions and methods for pain reduction
ZA200600025B (en) Methods and compositions for interferon therapy
EP1608385A4 (en) Therapeutic compositions
EP1503751A4 (en) Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
GB0303609D0 (en) Novel therapeutic method and compositions
EP1663255A4 (en) Withanamide and withanolide compositions and method of use thereof
EP1684771A4 (en) Composition and method
GB0222945D0 (en) Therapeutic compositions
GB0324523D0 (en) Compositions and methods of treatment
AU2003282722A8 (en) Therapeutic compositions
EP1583557A4 (en) Vaccine compositions and methods
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0327050D0 (en) Therapeutic methods compositions and uses
GB0303600D0 (en) Novel therapeutic method and compositions
GB0205826D0 (en) Therapeutic compositions and methods
GB0211831D0 (en) Therapeutic methods and compositions
GB0313059D0 (en) Compositions and method
GB0326870D0 (en) Therapeutic methods and compositions for use therein
GB0310251D0 (en) Therapeutic methods and compositions for use therein

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)